Web25 de nov. de 2024 · In this randomized, open-label, active-controlled, multicenter, phase 3 trial, eligible patients were randomized in a 2:1 ratio (based on a computer-generated … Web2 de jun. de 2024 · Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, …
Combined Statin-Ezetimibe for Elderly Adults With Atherosclerosis ...
Web12 de abr. de 2024 · The RACING trial was a prospective, multicenter, open-label, noninferiority trial, randomizing 3,780 patients with a history of ASCVD, from 26 centers in South Korea. Participants were randomized to either combination therapy with rosuvastatin 10 mg daily plus ezetimibe, or monotherapy with rosuvastatin 20 mg daily. WebThis study evaluated the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance therapy.Methods: Patients receiving inhaled COPD medication were enrolled in this multicenter, randomized, open-label, placebo-device, crossover study with a 2×2 … dictionary\u0027s pw
A phase 2, open‐label, randomized, multiple‐dose study …
Web25 de mai. de 2024 · KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with … Webwere randomized 1:1 to eribulin (1.4 mg/m2, IV on D1 and D8) or dacarbazine (850–1200 mg/m2, IV on D1) every 21 days until disease progression. Primary endpoint was OS. Secondary endpoints included PFS, PFS rate at Wk 12 and safety. Results: Overall, 452 pts (67% female; 79% < 65 yrs) were randomized (228 eribulin; 224 dacarbazine). Median Web5 de nov. de 2024 · BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress) Blood American Society of Hematology Abstract dictionary\u0027s q0